S-Labsp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2003-08-07
Share capital
100,000.00 PLN
Registered address
Kiełczowska 2, 55-095 Mirków, Poland
Electronic delivery address
AE:PL-12297-35582-EGRCH-25

Financials

Revenue history (in m)

Filing timeliness

No financial statement for 2022 – the filing deadline has passed. 1 of 4 financial statements was filed late (for 2021, 168 days late). All were audited by a statutory auditor.

  • 2022not filed
  • 202130/12/2022
  • 202015/10/2021
  • 201915/10/2020
  • 201805/07/2019
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2021.

Industry · Manufacture of pharmaceutical preparations59 / 258
Top 23%
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations60 / 330
Top 18%
Sector · Manufacturing4,793 / 33,744
Top 14%
Voivodeship · Dolnośląskie1,811 / 41,332
Top 4.4%
Country · Poland25,688 / 495,860
Top 5.2%

Results vs industry

Revenue
This companyUSD 10.06mMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD 133.73kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 9.83mMedianUSD 873.06kAverageUSD 21.43m
Assets
This companyUSD 7.32mMedianUSD 897.46kAverageUSD 31.52m

Industry

Public procurement

S-Lab is the contractor in one public sector contract, worth USD 156.13.

SubjectAmount
Purchase of medicinal products
$156.13

Trademarks

S-Lab holds 65 active trademarks registered with the Polish Patent Office. 2 applications are pending. 35 marks have expired or were not registered. The first mark was filed in 2003.

MarkNumberClassesStatusProtected until
OptiRetic(word)Z.5844245Protected May 9, 2035
Akneren Max(word)Z.5802393Protected Feb 10, 2035
SinaXto(word)Z.5697575Protected May 20, 2034
Altin(word)Z.5697585Protected May 20, 2034
Reseptic(word)Z.5697615Protected May 20, 2034
MarkProtected until
OptiRetic(word)May 9, 2035
Akneren Max(word)Feb 10, 2035
SinaXto(word)May 20, 2034
Altin(word)May 20, 2034
Reseptic(word)May 20, 2034

Authorized Representatives

Jarosław Sadłek – President of the Management Board
Wojciech Józef Sadłek – Attorney-in-fact (sole)

Manner of representation

In the case of a one-person management board, the President of the Management Board acts independently. In the case of a multi-member management board, joint action of two members of the management board, or one member of the management board jointly with a commercial proxy, is required to make declarations on behalf of the company.

Ownership

OwnerSharesShare valueStake
Jarosław Sadłekage 63
50$13,506.2150%
Wojciech Józef Sadłekage 59
50$13,506.2150%

Jarosław Sadłek and Wojciech Józef Sadłek hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2011-11-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$60,860
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$587K

Competitors

Name
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - LekS.A.
Wrocławskie Zakłady Zielarskie HerbapolS.A.
MedicofarmaS.A.
Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o.
Zeptor Polskasp. z o.o.
STEM Cells SpinS.A.
LideoS.A.
BIO Animalisp. z o.o.
Ampliconsp. z o.o.
Xenira Pharmaceuticalssp. z o.o.

Change history

DateEvent
2020-06-03Switch to PKD 2007
2003-08-07Entered in the register

FAQ

Last updated: 2026-04-08